Pubfacts - Scientific Publication Data
  • Categories
  • Journals
  • ->
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:
Get 20% Off Journals at LWW.com

Intracranial stenting of subacute symptomatic atherosclerotic occlusion versus stenosis.

Authors:
Peng-Hua Lü Jee Won Park Soonchan Park Jong Lim Kim Deok Hee Lee Sun Uck Kwon Jong Sung Kim Sung-Cheol Yun Dae Chul Suh

Stroke 2011 Dec 22;42(12):3470-6. Epub 2011 Sep 22.

Department of Radiology, University of Ulsan, College of Medicine, 86 Asanbyeongwon-Gil, Songpa-Gu, Seoul 138-736, Korea.

Background And Purpose: Limited data are available concerning the outcome of angioplasty/stenting for subacute atherosclerotic intracranial artery occlusion, which is often associated with progressive symptom development in the salvageable brain under ischemic threat due to poor collateral blood supply.

Methods: Among 177 patients who underwent angioplasty and/or stenting for severe symptomatic intracranial steno-occlusion, 26 had subacute atherosclerotic intracranial artery occlusion. Outcome after stenting (N=22) was assessed according to procedural success (return of antegrade flow and residual stenosis<50%), adverse event (any stroke or death) rate, and restenosis (>50%) using weighted Cox proportional hazards regression in the overall cohort and in separate subgroups.

Results: Successful recanalization was achieved in 95%. Three adverse events (13.6%) occurred among patients undergoing stenting for occlusion, including 2 major strokes and 1 nonprocedure-related death. Good outcome (modified Rankin Scale≤2) was achieved in 73%. In the overall cohort, no significant difference was observed between the occlusion and stenosis groups in terms of the risk of adverse events (hazard ratio for the occlusion group, 1.055; 95% CI, 0.29-3.90) or the risk of restenosis (hazard ratio for the occlusion group, 1.2; 95% CI, 0.19-7.72). A trend toward a higher rate of adverse events was observed in older age (>65 years), progressive worsening, balloon-expandable stent, and no history of a preprocedural P2Y12 assay.

Conclusions: In a cohort of patients undergoing angioplasty/stenting for subacute atherosclerotic intracranial artery occlusion, no significant difference in the rates of adverse events was observed. However, several factors, including age, tended to be associated with a higher event rate.

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.111.622282DOI Listing
December 2011

Publication Analysis

Top Keywords

adverse events
16
atherosclerotic intracranial
12
subacute atherosclerotic
12
intracranial artery
12
artery occlusion
12
events observed
8
hazard ratio
8
angioplasty/stenting subacute
8
ratio occlusion
8
occlusion group
8
patients undergoing
8
occlusion
8
intracranial
5
stenosis50% weighted
4
risk adverse
4
residual stenosis50%
4
cox proportional
4
hazards regression
4
events hazard
4
proportional hazards
4

Similar Publications

Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial.

Authors:
Jane Yardley Mikko Kärppä Yuichi Inoue Kate Pinner Carlos Perdomo Kohei Ishikawa Gleb Filippov Naoki Kubota Margaret Moline

Sleep Med 2021 Feb 1;80:333-342. Epub 2021 Feb 1.

Eisai Inc., 100 Tice Boulevard, Woodcliff Lake, NJ 07677, USA. Electronic address:

Objective/background: Lemborexant is a dual orexin receptor antagonist approved in the United States, Japan, and Canada for the treatment of insomnia in adults. We report effectiveness and safety outcomes in subjects with insomnia who received up to twelve months of continuous lemborexant treatment in Study E2006-G000-303 (Study 303; SUNRISE-2).

Patients/methods: Study 303 was a twelve-month, global, multicenter, randomized, double-blind, parallel-group, Phase 3 study divided into two treatment periods. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer.

Authors:
Haiying Cheng Yiyu Zou Chirag D Shah Ni Fan Tushar D Bhagat Rasim Gucalp Mimi Kim Amit Verma Bilal Piperdi Simon D Spivack Balazs Halmos Roman Perez-Soler

Lung Cancer 2021 Feb 17;154:99-104. Epub 2021 Feb 17.

Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY10461, USA. Electronic address:

Background: Aerosolized Azacitidine has been shown to inhibit orthotopic lung cancer growth and induce re-expression of methylated tumor suppressor genes in murine models. We hypothesized that inhaled Azacitidine is safe and effective in reversing epigenetic changes in the bronchial epithelium secondary to chronic smoking.

Patients And Methods: We report the first in human study of inhaled Azacitidine. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Safety and efficacy of arterially directed liver therapies in treatment of hepatic metastatic ovarian cancer: A retrospective single-institution study.

Authors:
Eduardo A Lacayo Sara Velayati Ahmed Elsakka Lynn Brody Joseph P Erinjeri Etay Ziv Franz E Boas Constantinos T Sofocleous Mikhail Silk Vicky Makker William P Tew Hooman Yarmohammadi

J Vasc Interv Radiol 2021 Feb 23. Epub 2021 Feb 23.

Department Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Purpose: To evaluate the safety and efficacy of two locoregional therapies (LRT) including hepatic artery embolization (HAE) and transarterial radioembolization (TARE) in treating patients with metastatic ovarian cancer to the liver.

Methods: From October 2010 to May 2019, the data of 15 consecutive patients (median age, 54 ± 9.8; range, 35-78) with hepatic metastatic ovarian cancer that were treated with either HAE (n = 6, 40%) or TARE (n = 9, 60%) were reviewed. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Phase II study of Enzalutamide with radiation therapy for intermediate risk prostate cancer: A phase 2 study.

Authors:
G J Bubley I Kaplan R Bhatt M-E Taplin S Dowling K Mahoney E Werner E P Nguyen

Int J Radiat Oncol Biol Phys 2021 Feb 23. Epub 2021 Feb 23.

Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School.

Background: Androgen deprivation therapy (ADT) is often used as adjuvant treatment with radiation therapy (RT) for intermediate-risk prostate cancer (PCa). ADT is associated with multiple side effects including weight gain, loss of libido and hot flashes. In contrast, anti-androgen monotherapy has been generally better tolerated. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Randomised Controlled Trial of a microneedle patch with a topical anaesthetic for relieving the pain of dental injections.

Authors:
Sinead Daly Nicholas C A Claydon Robert G Newcombe Joon Seong Martin Addy Nicola X West

J Dent 2021 Feb 23:103617. Epub 2021 Feb 23.

Clinical Trials Unit, Bristol Dental Hospital, Lower Maudlin Street, Bristol, BS1 2LY, United Kingdom. Electronic address:

Objectives: To determine whether a microneedle patch combined with 5% topical lidocaine reduces dental injection pain more than a patch without microneedles combined with 5% topical lidocaine.

Methods: This proof of principle randomised, two-treatment, double-blind, crossover split-unit design study in 16 healthy participants investigated levels of perceived pain from 3 increasing pain provoking challenges, when topical 5% lidocaine dental gel was applied to the oral mucosa with a microneedle patch and a patch with no microneedles, prior to infiltration with local anaesthesia on 2 visits. Pain was assessed by visual analogue scale (VAS) and 4-point verbal rating scale (VRS). Read More

View Article and Full-Text PDF
February 2021
Similar Publications
Save 15% Survey
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap